PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 54.53M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $54.53M | (m) | (m) |
| 2026-03-31 | (m) | $57.94M | (m) | (m) |
| 2025-12-31 | (m) | $9.68M | (m) | (m) |
| 2025-09-30 | (m) | $11.79M | (m) | (m) |
| 2025-06-30 | (m) | $10.34M | (m) | (m) |
| 2025-03-31 | (m) | $137.94M | (m) | (m) |
| 2024-12-31 | (m) | $135.16M | (m) | (m) |
| 2024-09-30 | (m) | $133.35M | (m) | (m) |
| 2024-06-30 | (m) | $217.25M | (m) | (m) |
| 2024-03-31 | (m) | $89.25M | (m) | (m) |
| 2023-12-31 | (m) | $91.37M | (m) | (m) |
| 2023-09-30 | (m) | $140.98M | (m) | (m) |
| 2023-06-30 | (m) | $57.63M | (m) | (m) |
| 2023-03-31 | (m) | $54.92M | (m) | (m) |
| 2022-12-31 | (m) | $53.91M | (m) | (m) |
| 2022-09-30 | (m) | $5.15M | (m) | (m) |
| 2022-06-30 | (m) | $142.81M | (m) | (m) |
| 2022-03-31 | (m) | $201.57M | (m) | (m) |
| 2021-12-31 | (m) | $200.58M | (m) | (m) |
| 2021-09-30 | (m) | $199.76M | (m) | (m) |
| 2021-06-30 | (m) | $60.75M | (m) | (m) |
| 2021-03-31 | (m) | $872.00K | (m) | (m) |
| 2020-12-31 | (m) | $853.00K | (m) | (m) |
| 2020-09-30 | (m) | $749.00K | (m) | (m) |
| 2020-06-30 | (m) | $797.00K | (m) | (m) |
| 2020-03-31 | (m) | $769.00K | (m) | (m) |
| 2019-12-31 | (m) | $814.00K | (m) | (m) |
| 2019-09-30 | (m) | $752.00K | (m) | (m) |
| 2019-06-30 | (m) | $802.00K | (m) | (m) |
| 2019-03-31 | (m) | $914.00K | (m) | (m) |
| 2018-12-31 | (m) | $955.00K | (m) | (m) |
| 2018-09-30 | (m) | $990.00K | (m) | (m) |
| 2018-06-30 | (m) | $954.00K | (m) | (m) |
| 2018-03-31 | (m) | $27.49M | (m) | (m) |
| 2017-12-31 | (m) | $27.52M | (m) | (m) |
| 2017-09-30 | (m) | $27.46M | (m) | (m) |
| 2017-06-30 | (m) | $27.53M | (m) | (m) |
| 2017-03-31 | (m) | $1.05M | (m) | (m) |
| 2016-12-31 | (m) | $1.05M | (m) | (m) |
| 2016-09-30 | (m) | $1.19M | (m) | (m) |
| 2016-06-30 | (m) | $1.33M | (m) | (m) |
| 2016-03-31 | (m) | $1.28M | (m) | (m) |
| 2015-12-31 | (m) | $1.61M | (m) | (m) |
| 2015-09-30 | (m) | $3.31M | (m) | (m) |
| 2015-06-30 | (m) | $4.37M | (m) | (m) |
| 2015-03-31 | (m) | $19.21M | (m) | (m) |
| 2014-12-31 | (m) | $50.85M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $676.00K | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $2.66M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |